The main findings in this study were that overall mortality among patients triggering the MET was high. More than one out of four patients died within 30 days, and the higher the age, the greater the mortality, independent of gender. The medical conditions of patients, such as haematological disease, liver disease, cancer and renal failure, were independently and significantly associated with increased 30-day mortality. The laboratory biomarkers corresponding to the highest mortality risk were hypoglycaemia, hyperlactataemia, anaemia and hypoxaemia. In addition, this study implied the importance of several other factors associated with mortality in clinically deteriorating patients, including abnormal vital parameters such as hypoxia and tachypnoea, level of consciousness and type of ward activating the MET. Overall, thirteen factors independently associated with 30-day mortality were identified, that could be applied for risk stratification and prediction of death within 30 days in MET assessed patients, with acceptable discrimination and performance (median AUC = 0.768 corrected to optimism).
To demonstrate independent risk factors, multivariable analyses were performed. Due to the large quantity of included variables, more than half the study population was excluded from the complete data analysis, as a result of missing data on one or more of these variables (Additional file 11). Therefore, a multivariable analysis using multiple imputations was performed (Table 1). Regardless of the method, the results of both multivariable analyses were consistent with those of the analyses of each variable separately.
The notably high mortality rate in this MET population could be explained by the possibly life-threatening situation of clinical deterioration in combination with advanced age and numerous co-morbidities. As stated in previous studies, MET patients are in the poorest condition among hospitalised patients with high in-hospital and 30-day death rates [1, 11]. Analogously, the type of ward demonstrating by far the highest risk of death among admitted patients was the geriatric wards (Additional file 4). More than half of the clinically deteriorated geriatric patients triggering the MET died within 30 days after assessment. Given the indisputable importance of age in relation to survival, the potentially beneficial contribution of the patient's age as a trigger component in the early warning system cannot be ignored. In this context, it is worth pointing out that although there is a strong correlation between age and survival, it does not necessarily indicate that all elderly patients should be given immediate priority to the ICU. A risk assessment based on the significance of age may be further refined by the inclusion of a frailty index for better adjustment of the age factor to reality [12]. Furthermore, some elderly patients with a particularly high risk of death may be candidates for decisions on LOMT and do not attempt cardiopulmonary resuscitation rather than a higher level of care. Such difficult, but important, decisions in the final stages of life may be facilitated through other decision support tools [13]. However, that kind of reasoning should preferably be processed before alerting the MET.
The association between the type of ward for admittance and mortality reflects the commonly found medical conditions. It appears that medical and surgical wards tend to utilise the MET to about the same extent, although the difference in outcome was striking in our study. The overall 30-day mortality on medical wards was almost twice as high as that on surgical wards. Consequently, the patient's place of care may be indicative of the end of the course, in terms of mortality, as medical ward patients proved to have a significantly increased risk of death. The difference in 30-day mortality between surgical and medical ward patients could be explained in part by the fact that surgical patients tended to have less co-morbidity and more of an isolated problem (Additional file 12).
The most frequently used trigger criterion was peripheral capillary oxygen saturation (SpO2) < 90% (Additional file 13). Interestingly, the incidence of SpO2 < 90% decreased by almost 10 per cent between MET activation and arrival (Additional file 8), which is believed to depend on the independent administration of oxygen by ward nurses and possibly also oxygen treatment recommendations over the phone pending the arrival of the MET. Despite this initial sign of improved optimisation, hypoxia and tachypnoea were associated with higher 30-day mortality among vital parameters, which strengthens the findings in previous studies [14]. Curiously, circulatory parameters did not play as important a role in predicting outcome in the MET patient population.
Caution should be taken concerning the fact that one of the vital parameters of the utmost importance in predicting 30-day mortality, i.e. the respiratory rate, was the parameter most often missing in the MET protocol – missing in more than every fifth patient. Respiratory abnormalities, such as tachypnoea and dyspnea, are well-recognised early warning signs in critically ill patients at risk of clinical deterioration and cardiac arrest [15, 16]. Considering the significant mortality risk when a patient presents with an elevated respiratory rate, we call for more attention to be paid to monitoring this vital parameter.
Despite hypoglycaemia being the most rarely encountered abnormal biomarker, it was associated with the highest mortality risk of all measured risk factors. Hypoglycaemia has previously been shown in several studies to be an independent risk factor for death in patients with acute illness [17,18,19]. Hence, it appears that disturbances in glucose metabolism signify an increased risk of adverse outcomes among critically ill patients. Other biomarkers associated with poor outcomes were hyperlactataemia, hypoxaemia and anaemia (Table 1). All the mortality-indicative biomarkers are found in regular blood gas analyses. Our data, however, revealed that arterial blood gases were missing during the care event for 40% of the patients. Routine arterial blood gas sampling was not included in the protocol. Instead, arterial blood gas sampling was performed depending on the clinician's assessment of the individual patient's clinical status. These variable circumstances lead us to speculate about whether more frequent blood gas sampling in clinically compromised patients would be beneficial for the early detection of severe illness and, by extension, improved outcome.
Risk score for mortality
Previous prognostic risk scores within the MET field have only been presented to a limited extent, principally under dissimilar conditions or with differing endpoints, such as ICU admission and cardiac arrest [20, 21]. However, in parallel, a comparable study has been conducted in Australia, which supports our findings in a Scandinavian setting [22]. Similarly, a risk score was developed from the predictors in the multivariable regression model, with acceptable performance in estimating the probability of death following MET assessment. Thus, the concept of a risk score protocol could be a successful way to assist clinicians in identifying critically ill patients, optimising their care and ultimately reducing mortality.
The developed risk score showed a median AUC of 0.768 when corrected for optimism and the goodness of fit test indicated good calibration. Still, using the median risk score (= 14 points) as cut-off, specificity and PPV were rather low (less than two-thirds and less than half, respectively), indicating there is room for improvement. Even though the scoring system successfully identifies predictors, its accuracy still needs to be externally validated before it can be generally recommended in clinical practice. Subsequently, a refinement of the decision support can be achieved by monitoring trends of inpatients, with the use of artificial intelligence and machine learning techniques.
Clinical implications
When patients are assessed by a MET team and triaged to the optimal level of care, several clinical factors are taken into account as decision support. The clinicians’ approach to further treatment will most likely differ, depending on experience and expertise. To achieve a more coherent handling of each patient case based on their condition, a risk scoring system, as described in this article, could be a useful tool in the decision-making process. The purpose of a risk score would be to serve as support for the clinician in prognosis prediction and mortality risk assessment, as a basis for the decision on treatment measures and escalation of the level of care. The purpose of a risk score is not to be a sole decision tool, but rather an additional part of all factors taken into account in the final decision-making. A large number of patient-related factors will contribute important information in the creation of a reliable risk score, including; age, type of ward for admittance, previous medical history, acute medical conditions, laboratory biomarkers, vital parameters and other clinical findings. The development of a risk score tool is still in the initial phase, thus, it needs to be emphasised that the risk score described in this article needs further testing and validation on larger sample sizes before final implementation in clinical practice. Also, with the help of artificial intelligence and machine learning techniques, it is probably possible to further improve the accuracy of the model [23,24,25]. In addition, hospital-specific risk scores may need to be developed for logistical reasons, such as varying patient cohorts in the wards. With these considerations in mind, the availability of a standardised risk score for the estimation of the mortality risk at MET assessment should be favourable from a prioritisation and optimisation perspective.
Study strengths and limitations
Strengths
The study was population-based with well-defined inclusion and exclusion criteria and a relatively large sample size. Furthermore, it was consecutive, and all cases were evaluated for inclusion. Moreover, it was chart based, with all cases handled manually.
Limitations
Data were limited to 2010–2015, and new conditions may have emerged since then. The 'MET dose', calculated as the number of MET assessments divided by the number of hospital admissions (approximately 12/1,000), was low in comparison to studies in other healthcare systems, possibly indicating an inefficiency in the system [26]. Despite this, our 'MET dose' is higher than the dose previously reported in a before-and-after trial in Sweden, where the implementation of MET was associated with a significant improvement in cardiac arrest rate and in-hospital mortality [27]. Given the retrospective design, it was not possible to check and correct for afferent limb failure, i.e. delayed activation of the MET [28]. Further, it was a single-centre study using a single-parameter system, not fully transferable to hospitals with different routines. Since it was a retrospective study, we were not able to control for unmeasured factors. Also, for several of the variables, the number of missing data was substantial, although we tried to handle this by using multiple imputation methods in the multivariable analysis. In a retrospective register study, it is not possible to draw any conclusion regarding the cause and the effect. We are only able to describe associations.